CA2987889A1 - T cell receptor like antibodies having fine specificity - Google Patents

Info

Publication number

CA2987889A1

CA2987889A1 CA2987889A CA2987889A CA2987889A1 CA 2987889 A1 CA2987889 A1 CA 2987889A1 CA 2987889 A CA2987889 A CA 2987889A CA 2987889 A CA2987889 A CA 2987889A CA 2987889 A1 CA2987889 A1 CA 2987889A1

Authority

CA

Canada

Prior art keywords

hla

antibody

binding

peptide

cells

Prior art date

2015-06-08

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 108091008874 T cell receptors Proteins 0.000 title description 33
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 title description 33
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 769
• 230000027455 binding Effects 0.000 claims abstract description 434
• 239000000427 antigen Substances 0.000 claims abstract description 195
• 102000036639 antigens Human genes 0.000 claims abstract description 192
• 108091007433 antigens Proteins 0.000 claims abstract description 191
• 108700018351 Major Histocompatibility Complex Proteins 0.000 claims abstract description 120
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims abstract description 120
• 125000000539 amino acid group Chemical group 0.000 claims abstract description 87
• 241000282414 Homo sapiens Species 0.000 claims abstract description 79
• 238000006467 substitution reaction Methods 0.000 claims abstract description 74
• 230000009467 reduction Effects 0.000 claims abstract description 36
• 238000001943 fluorescence-activated cell sorting Methods 0.000 claims abstract description 34
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 300
• 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 226
• 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 226
• 108060008724 Tyrosinase Proteins 0.000 claims description 122
• 102000003425 Tyrosinase Human genes 0.000 claims description 122
• 238000000034 method Methods 0.000 claims description 96
• 206010028980 Neoplasm Diseases 0.000 claims description 89
• 235000001014 amino acid Nutrition 0.000 claims description 84
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 80
• 150000001413 amino acids Chemical group 0.000 claims description 55
• 235000004279 alanine Nutrition 0.000 claims description 47
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 31
• 238000003556 assay Methods 0.000 claims description 27
• 201000011510 cancer Diseases 0.000 claims description 27
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
• 230000003612 virological effect Effects 0.000 claims description 25
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 23
• 230000001225 therapeutic effect Effects 0.000 claims description 23
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 22
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 claims description 19
• 229920001184 polypeptide Polymers 0.000 claims description 19
• 239000013604 expression vector Substances 0.000 claims description 18
• 150000007523 nucleic acids Chemical group 0.000 claims description 17
• 108091033319 polynucleotide Proteins 0.000 claims description 14
• 102000040430 polynucleotide Human genes 0.000 claims description 14
• 239000002157 polynucleotide Substances 0.000 claims description 14
• 239000004471 Glycine Substances 0.000 claims description 11
• 230000001363 autoimmune Effects 0.000 claims description 10
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 9
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 9
• 238000002825 functional assay Methods 0.000 claims description 9
• 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 8
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
• 238000000126 in silico method Methods 0.000 claims description 7
• 239000004474 valine Substances 0.000 claims description 7
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
• 230000001105 regulatory effect Effects 0.000 claims description 6
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 4
• 210000004027 cell Anatomy 0.000 description 387
• 238000000684 flow cytometry Methods 0.000 description 68
• 210000000612 antigen-presenting cell Anatomy 0.000 description 66
• 101100424688 Arabidopsis thaliana ESK1 gene Proteins 0.000 description 64
• 239000004698 Polyethylene Substances 0.000 description 63
• 230000014509 gene expression Effects 0.000 description 59
• 229940024606 amino acid Drugs 0.000 description 53
• 102100033107 Growth factor receptor-bound protein 7 Human genes 0.000 description 49
• 210000001519 tissue Anatomy 0.000 description 47
• 201000001441 melanoma Diseases 0.000 description 42
• 210000001744 T-lymphocyte Anatomy 0.000 description 41
• 108090000623 proteins and genes Proteins 0.000 description 40
• 102100034937 Poly(A) RNA polymerase, mitochondrial Human genes 0.000 description 35
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 33
• 206010022000 influenza Diseases 0.000 description 33
• 238000004458 analytical method Methods 0.000 description 30
• 238000012867 alanine scanning Methods 0.000 description 28
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 25
• 210000004408 hybridoma Anatomy 0.000 description 25
• 102000004169 proteins and genes Human genes 0.000 description 25
• 210000004881 tumor cell Anatomy 0.000 description 25
• 238000011068 loading method Methods 0.000 description 24
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 24
• 235000018102 proteins Nutrition 0.000 description 24
• 230000007423 decrease Effects 0.000 description 23
• 201000010099 disease Diseases 0.000 description 23
• 239000000203 mixture Substances 0.000 description 23
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 22
• 239000012634 fragment Substances 0.000 description 22
• 230000035772 mutation Effects 0.000 description 22
• 210000004556 brain Anatomy 0.000 description 21
• 239000012636 effector Substances 0.000 description 21
• 230000011664 signaling Effects 0.000 description 21
• 230000001086 cytosolic effect Effects 0.000 description 20
• 230000009257 reactivity Effects 0.000 description 19
• 230000006870 function Effects 0.000 description 18
• 239000003446 ligand Substances 0.000 description 18
• 238000000338 in vitro Methods 0.000 description 17
• 230000007170 pathology Effects 0.000 description 17
• 239000004480 active ingredient Substances 0.000 description 16
• 239000008194 pharmaceutical composition Substances 0.000 description 16
• 108010090804 Streptavidin Proteins 0.000 description 15
• 238000011156 evaluation Methods 0.000 description 15
• 201000006417 multiple sclerosis Diseases 0.000 description 15
• -1 HLA-A34 Proteins 0.000 description 14
• 241000699666 Mus <mouse, genus> Species 0.000 description 14
• 238000002347 injection Methods 0.000 description 14
• 239000007924 injection Substances 0.000 description 14
• 239000003814 drug Substances 0.000 description 13
• 238000011534 incubation Methods 0.000 description 13
• 230000002147 killing effect Effects 0.000 description 13
• 102000039446 nucleic acids Human genes 0.000 description 13
• 108020004707 nucleic acids Proteins 0.000 description 13
• 108010002382 pilose antler peptide Proteins 0.000 description 13
• 239000000126 substance Substances 0.000 description 13
• 208000023275 Autoimmune disease Diseases 0.000 description 12
• 241000701022 Cytomegalovirus Species 0.000 description 12
• 238000013459 approach Methods 0.000 description 12
• 230000021615 conjugation Effects 0.000 description 12
• 230000001419 dependent effect Effects 0.000 description 12
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
• 208000032839 leukemia Diseases 0.000 description 12
• 108020004999 messenger RNA Proteins 0.000 description 12
• 239000002953 phosphate buffered saline Substances 0.000 description 12
• 102000005962 receptors Human genes 0.000 description 12
• 108020003175 receptors Proteins 0.000 description 12
• 102000004190 Enzymes Human genes 0.000 description 11
• 108090000790 Enzymes Proteins 0.000 description 11
• 108060003951 Immunoglobulin Proteins 0.000 description 11
• 238000005516 engineering process Methods 0.000 description 11
• 229940088598 enzyme Drugs 0.000 description 11
• 102000018358 immunoglobulin Human genes 0.000 description 11
• 230000003834 intracellular effect Effects 0.000 description 11
• 238000005259 measurement Methods 0.000 description 11
• 239000006228 supernatant Substances 0.000 description 11
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
• 241000588724 Escherichia coli Species 0.000 description 10
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 10
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 10
• 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 10
• 230000000694 effects Effects 0.000 description 10
• 239000012091 fetal bovine serum Substances 0.000 description 10
• 210000003734 kidney Anatomy 0.000 description 10
• 210000004072 lung Anatomy 0.000 description 10
• 238000002360 preparation method Methods 0.000 description 10
• 230000035945 sensitivity Effects 0.000 description 10
• 238000002965 ELISA Methods 0.000 description 9
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 9
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 9
• 230000004913 activation Effects 0.000 description 9
• 238000012512 characterization method Methods 0.000 description 9
• 238000006243 chemical reaction Methods 0.000 description 9
• 210000000936 intestine Anatomy 0.000 description 9
• 210000004185 liver Anatomy 0.000 description 9
• 238000004949 mass spectrometry Methods 0.000 description 9
• 239000002773 nucleotide Substances 0.000 description 9
• 125000003729 nucleotide group Chemical group 0.000 description 9
• 210000002307 prostate Anatomy 0.000 description 9
• 238000003753 real-time PCR Methods 0.000 description 9
• 201000009030 Carcinoma Diseases 0.000 description 8
• 241000699670 Mus sp. Species 0.000 description 8
• 210000003719 b-lymphocyte Anatomy 0.000 description 8
• 230000015572 biosynthetic process Effects 0.000 description 8
• 239000003795 chemical substances by application Substances 0.000 description 8
• 210000001072 colon Anatomy 0.000 description 8
• 150000001875 compounds Chemical class 0.000 description 8
• 210000001198 duodenum Anatomy 0.000 description 8
• 238000001727 in vivo Methods 0.000 description 8
• 238000004519 manufacturing process Methods 0.000 description 8
• 230000004044 response Effects 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 230000004936 stimulating effect Effects 0.000 description 8
• 230000008685 targeting Effects 0.000 description 8
• 230000005740 tumor formation Effects 0.000 description 8
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
• 108091054437 MHC class I family Proteins 0.000 description 7
• 108020004511 Recombinant DNA Proteins 0.000 description 7
• 208000036142 Viral infection Diseases 0.000 description 7
• 239000012491 analyte Substances 0.000 description 7
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 7
• 210000003710 cerebral cortex Anatomy 0.000 description 7
• 238000010367 cloning Methods 0.000 description 7
• 238000001514 detection method Methods 0.000 description 7
• 102000054766 genetic haplotypes Human genes 0.000 description 7
• 210000002216 heart Anatomy 0.000 description 7
• 230000004068 intracellular signaling Effects 0.000 description 7
• 238000002955 isolation Methods 0.000 description 7
• 239000002609 medium Substances 0.000 description 7
• 210000001525 retina Anatomy 0.000 description 7
• 210000002784 stomach Anatomy 0.000 description 7
• 238000007920 subcutaneous administration Methods 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 230000001988 toxicity Effects 0.000 description 7
• 231100000419 toxicity Toxicity 0.000 description 7
• 230000032258 transport Effects 0.000 description 7
• 210000004291 uterus Anatomy 0.000 description 7
• 239000013598 vector Substances 0.000 description 7
• 230000009385 viral infection Effects 0.000 description 7
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 6
• 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 6
• 241000713196 Influenza B virus Species 0.000 description 6
• 206010025323 Lymphomas Diseases 0.000 description 6
• 102000043129 MHC class I family Human genes 0.000 description 6
• 206010035226 Plasma cell myeloma Diseases 0.000 description 6
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 6
• 241000700605 Viruses Species 0.000 description 6
• 210000000481 breast Anatomy 0.000 description 6
• 150000001718 carbodiimides Chemical class 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• 210000001638 cerebellum Anatomy 0.000 description 6
• 210000004720 cerebrum Anatomy 0.000 description 6
• 238000012761 co-transfection Methods 0.000 description 6
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
• 238000009472 formulation Methods 0.000 description 6
• 230000000670 limiting effect Effects 0.000 description 6
• 210000000822 natural killer cell Anatomy 0.000 description 6
• 210000005036 nerve Anatomy 0.000 description 6
• 238000002823 phage display Methods 0.000 description 6
• 239000000546 pharmaceutical excipient Substances 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 210000000952 spleen Anatomy 0.000 description 6
• 210000001550 testis Anatomy 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• 206010006187 Breast cancer Diseases 0.000 description 5
• 208000026310 Breast neoplasm Diseases 0.000 description 5
• 108010010803 Gelatin Proteins 0.000 description 5
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 5
• 108060003393 Granulin Proteins 0.000 description 5
• 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 5
• 241000712431 Influenza A virus Species 0.000 description 5
• 102000003855 L-lactate dehydrogenase Human genes 0.000 description 5
• 108700023483 L-lactate dehydrogenases Proteins 0.000 description 5
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 5
• 102000057297 Pepsin A Human genes 0.000 description 5
• 108090000284 Pepsin A Proteins 0.000 description 5
• 108010081208 RMFPNAPYL Proteins 0.000 description 5
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 5
• 238000011579 SCID mouse model Methods 0.000 description 5
• 206010039491 Sarcoma Diseases 0.000 description 5
• 101150117538 Set2 gene Proteins 0.000 description 5
• 229920002472 Starch Polymers 0.000 description 5
• 230000000890 antigenic effect Effects 0.000 description 5
• 239000011230 binding agent Substances 0.000 description 5
• 230000004071 biological effect Effects 0.000 description 5
• 238000007413 biotinylation Methods 0.000 description 5
• 230000006287 biotinylation Effects 0.000 description 5
• 239000002775 capsule Substances 0.000 description 5
• 229910002092 carbon dioxide Inorganic materials 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 238000004113 cell culture Methods 0.000 description 5
• 230000000139 costimulatory effect Effects 0.000 description 5
• 230000003013 cytotoxicity Effects 0.000 description 5
• 231100000135 cytotoxicity Toxicity 0.000 description 5
• 210000004443 dendritic cell Anatomy 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 210000003162 effector t lymphocyte Anatomy 0.000 description 5
• 229920000159 gelatin Polymers 0.000 description 5
• 239000008273 gelatin Substances 0.000 description 5
• 235000019322 gelatine Nutrition 0.000 description 5
• 235000011852 gelatine desserts Nutrition 0.000 description 5
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• 230000001817 pituitary effect Effects 0.000 description 5
• 230000008488 polyadenylation Effects 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 239000000523 sample Substances 0.000 description 5
• 210000003491 skin Anatomy 0.000 description 5
• 210000000278 spinal cord Anatomy 0.000 description 5
• 230000002269 spontaneous effect Effects 0.000 description 5
• 239000000758 substrate Substances 0.000 description 5
• 238000013518 transcription Methods 0.000 description 5
• 238000011144 upstream manufacturing Methods 0.000 description 5
• JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 4
• 101100218322 Arabidopsis thaliana ATXR3 gene Proteins 0.000 description 4
• 102000003886 Glycoproteins Human genes 0.000 description 4
• 108090000288 Glycoproteins Proteins 0.000 description 4
• 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 101001001462 Homo sapiens Importin subunit alpha-5 Proteins 0.000 description 4
• 101100149326 Homo sapiens SETD2 gene Proteins 0.000 description 4
• 102100036186 Importin subunit alpha-5 Human genes 0.000 description 4
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 4
• 108010037274 Member 9 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 description 4
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
• 102000011931 Nucleoproteins Human genes 0.000 description 4
• 108010061100 Nucleoproteins Proteins 0.000 description 4
• 101100533304 Plasmodium falciparum (isolate 3D7) SETVS gene Proteins 0.000 description 4
• 206010060862 Prostate cancer Diseases 0.000 description 4
• 108700009124 Transcription Initiation Site Proteins 0.000 description 4
• 230000000259 anti-tumor effect Effects 0.000 description 4
• 238000003776 cleavage reaction Methods 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 239000008298 dragée Substances 0.000 description 4
• 239000003623 enhancer Substances 0.000 description 4
• 210000003238 esophagus Anatomy 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 210000000232 gallbladder Anatomy 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 230000036210 malignancy Effects 0.000 description 4
• 230000004048 modification Effects 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• 210000001672 ovary Anatomy 0.000 description 4
• 210000000496 pancreas Anatomy 0.000 description 4
• 244000052769 pathogen Species 0.000 description 4
• 230000001717 pathogenic effect Effects 0.000 description 4
• 230000000144 pharmacologic effect Effects 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 description 4
• 230000007017 scission Effects 0.000 description 4
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
• 239000003381 stabilizer Substances 0.000 description 4
• 235000019698 starch Nutrition 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 125000003396 thiol group Chemical group [H]S* 0.000 description 4
• 230000035897 transcription Effects 0.000 description 4
• 239000003981 vehicle Substances 0.000 description 4
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
• 108700028369 Alleles Proteins 0.000 description 3
• 102000006306 Antigen Receptors Human genes 0.000 description 3
• 108010083359 Antigen Receptors Proteins 0.000 description 3
• 101150013553 CD40 gene Proteins 0.000 description 3
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
• 102100035793 CD83 antigen Human genes 0.000 description 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• 108020004414 DNA Proteins 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 101710154606 Hemagglutinin Proteins 0.000 description 3
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
• 241000711549 Hepacivirus C Species 0.000 description 3
• 102100039999 Histone deacetylase 2 Human genes 0.000 description 3
• 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 3
• 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 3
• 101000781876 Homo sapiens Zinc finger protein 518A Proteins 0.000 description 3
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 102100022430 Melanocyte protein PMEL Human genes 0.000 description 3
• 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 3
• 108010052285 Membrane Proteins Proteins 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• 208000034578 Multiple myelomas Diseases 0.000 description 3
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 3
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 3
• 206010033128 Ovarian cancer Diseases 0.000 description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 description 3
• 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
• 101710176177 Protein A56 Proteins 0.000 description 3
• 108010076504 Protein Sorting Signals Proteins 0.000 description 3
• 239000012980 RPMI-1640 medium Substances 0.000 description 3
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
• 108091006629 SLC13A2 Proteins 0.000 description 3
• 108010022394 Threonine synthase Proteins 0.000 description 3
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
• 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 3
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
• 102100036690 Zinc finger protein 518A Human genes 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• 230000001919 adrenal effect Effects 0.000 description 3
• 238000001042 affinity chromatography Methods 0.000 description 3
• 210000001130 astrocyte Anatomy 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 230000022534 cell killing Effects 0.000 description 3
• 210000003169 central nervous system Anatomy 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 238000010276 construction Methods 0.000 description 3
• 239000012228 culture supernatant Substances 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
• 231100000433 cytotoxic Toxicity 0.000 description 3
• 230000001472 cytotoxic effect Effects 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 102000004419 dihydrofolate reductase Human genes 0.000 description 3
• 208000035475 disorder Diseases 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 238000010828 elution Methods 0.000 description 3
• 210000003038 endothelium Anatomy 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 230000004927 fusion Effects 0.000 description 3
• 239000000185 hemagglutinin Substances 0.000 description 3
• 210000005260 human cell Anatomy 0.000 description 3
• 210000002865 immune cell Anatomy 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 229940072221 immunoglobulins Drugs 0.000 description 3
• 238000009169 immunotherapy Methods 0.000 description 3
• 238000012405 in silico analysis Methods 0.000 description 3
• 210000003000 inclusion body Anatomy 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 229910052751 metal Inorganic materials 0.000 description 3
• 239000002184 metal Substances 0.000 description 3
• 238000010369 molecular cloning Methods 0.000 description 3
• 201000000050 myeloid neoplasm Diseases 0.000 description 3
• 239000013642 negative control Substances 0.000 description 3
• 108010087904 neutravidin Proteins 0.000 description 3
• 231100001083 no cytotoxicity Toxicity 0.000 description 3
• 201000008968 osteosarcoma Diseases 0.000 description 3
• 208000008443 pancreatic carcinoma Diseases 0.000 description 3
• 229940111202 pepsin Drugs 0.000 description 3
• 239000013641 positive control Substances 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 201000001514 prostate carcinoma Diseases 0.000 description 3
• 238000012797 qualification Methods 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 125000006850 spacer group Chemical group 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 2
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
• GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 description 2
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
• 102100023990 60S ribosomal protein L17 Human genes 0.000 description 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
• 201000004384 Alopecia Diseases 0.000 description 2
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
• 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
• 208000023328 Basedow disease Diseases 0.000 description 2
• 206010005003 Bladder cancer Diseases 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 208000003174 Brain Neoplasms Diseases 0.000 description 2
• 102100027207 CD27 antigen Human genes 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
• 102100026548 Caspase-8 Human genes 0.000 description 2
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• 208000010975 Dystrophic epidermolysis bullosa Diseases 0.000 description 2
• 238000012286 ELISA Assay Methods 0.000 description 2
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
• 206010018338 Glioma Diseases 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• 102000006771 Gonadotropins Human genes 0.000 description 2
• 108010086677 Gonadotropins Proteins 0.000 description 2
• 102100033505 Granule associated Rac and RHOG effector protein 1 Human genes 0.000 description 2
• 208000015023 Graves' disease Diseases 0.000 description 2
• 108010091938 HLA-B7 Antigen Proteins 0.000 description 2
• 208000001204 Hashimoto Disease Diseases 0.000 description 2
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
• 101000870788 Homo sapiens Granule associated Rac and RHOG effector protein 1 Proteins 0.000 description 2
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
• 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 2
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
• 101000738335 Homo sapiens T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 description 2
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
• 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 2
• 241001318803 Human T-lymphotropic virus 4 Species 0.000 description 2
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
• 102000004310 Ion Channels Human genes 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• 101150113776 LMP1 gene Proteins 0.000 description 2
• 102100039648 Lactadherin Human genes 0.000 description 2
• 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 108091054438 MHC class II family Proteins 0.000 description 2
• 102000043131 MHC class II family Human genes 0.000 description 2
• 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
• 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
• 102000018697 Membrane Proteins Human genes 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
• 206010028665 Myxoedema Diseases 0.000 description 2
• 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 2
• 241001644525 Nastus productus Species 0.000 description 2
• 102000005348 Neuraminidase Human genes 0.000 description 2
• 108010006232 Neuraminidase Proteins 0.000 description 2
• 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
• 102000015636 Oligopeptides Human genes 0.000 description 2
• 108010038807 Oligopeptides Proteins 0.000 description 2
• 108700020796 Oncogene Proteins 0.000 description 2
• 102000043276 Oncogene Human genes 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• 108090000526 Papain Proteins 0.000 description 2
• 206010034038 Parotitis Diseases 0.000 description 2
• 201000011152 Pemphigus Diseases 0.000 description 2
• 208000031845 Pernicious anaemia Diseases 0.000 description 2
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• 208000006045 Spondylarthropathies Diseases 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• 102100037906 T-cell surface glycoprotein CD3 zeta chain Human genes 0.000 description 2
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
• 108700026226 TATA Box Proteins 0.000 description 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
• 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
• 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
• 229940127174 UCHT1 Drugs 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• 102100038849 Uroplakin-1a Human genes 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 2
• 108010067390 Viral Proteins Proteins 0.000 description 2
• 206010047642 Vitiligo Diseases 0.000 description 2
• 208000008383 Wilms tumor Diseases 0.000 description 2
• 102100022748 Wilms tumor protein Human genes 0.000 description 2
• 238000011467 adoptive cell therapy Methods 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 125000001931 aliphatic group Chemical group 0.000 description 2
• 231100000360 alopecia Toxicity 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 210000004102 animal cell Anatomy 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 239000012298 atmosphere Substances 0.000 description 2
• 230000000599 auto-anti-genic effect Effects 0.000 description 2
• 230000006472 autoimmune response Effects 0.000 description 2
• 230000005784 autoimmunity Effects 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 201000001531 bladder carcinoma Diseases 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 210000005013 brain tissue Anatomy 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 210000004413 cardiac myocyte Anatomy 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 230000000112 colonic effect Effects 0.000 description 2
• 230000000295 complement effect Effects 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 239000013068 control sample Substances 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 230000001461 cytolytic effect Effects 0.000 description 2
• 238000002784 cytotoxicity assay Methods 0.000 description 2
• 231100000263 cytotoxicity test Toxicity 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 238000010494 dissociation reaction Methods 0.000 description 2
• 230000005593 dissociations Effects 0.000 description 2
• 230000003828 downregulation Effects 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 210000002889 endothelial cell Anatomy 0.000 description 2
• 210000003979 eosinophil Anatomy 0.000 description 2
• 208000004298 epidermolysis bullosa dystrophica Diseases 0.000 description 2
• 201000010063 epididymitis Diseases 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 239000010685 fatty oil Substances 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 239000000945 filler Substances 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 239000011888 foil Substances 0.000 description 2
• 108020001507 fusion proteins Proteins 0.000 description 2
• 102000037865 fusion proteins Human genes 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
• 208000005017 glioblastoma Diseases 0.000 description 2
• 239000002622 gonadotropin Substances 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 244000000013 helminth Species 0.000 description 2
• 201000005787 hematologic cancer Diseases 0.000 description 2
• 208000007475 hemolytic anemia Diseases 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• 210000003494 hepatocyte Anatomy 0.000 description 2
• 108010007811 human immunodeficiency virus p17 gag peptide Proteins 0.000 description 2
• 239000012642 immune effector Substances 0.000 description 2
• 229940121354 immunomodulator Drugs 0.000 description 2
• 230000001024 immunotherapeutic effect Effects 0.000 description 2
• 230000008676 import Effects 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 208000037797 influenza A Diseases 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 238000011081 inoculation Methods 0.000 description 2
• 238000002843 lactate dehydrogenase assay Methods 0.000 description 2
• 208000020816 lung neoplasm Diseases 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• 208000003786 myxedema Diseases 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 125000004433 nitrogen atom Chemical group N* 0.000 description 2
• 230000009871 nonspecific binding Effects 0.000 description 2
• 201000002528 pancreatic cancer Diseases 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 201000001976 pemphigus vulgaris Diseases 0.000 description 2
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• 108010036385 plasmin-plasmin inhibitor complex Proteins 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 108010002730 protein S precursor Proteins 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 201000003068 rheumatic fever Diseases 0.000 description 2
• 239000012146 running buffer Substances 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 201000000306 sarcoidosis Diseases 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 238000010187 selection method Methods 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 210000004988 splenocyte Anatomy 0.000 description 2
• 201000005671 spondyloarthropathy Diseases 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 230000002483 superagonistic effect Effects 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 206010043778 thyroiditis Diseases 0.000 description 2
• 239000012096 transfection reagent Substances 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 230000003827 upregulation Effects 0.000 description 2
• 208000010570 urinary bladder carcinoma Diseases 0.000 description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• AHOKKYCUWBLDST-QYULHYBRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=CC=C1 AHOKKYCUWBLDST-QYULHYBRSA-N 0.000 description 1
• JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 1
• POVNCJSPYFCWJR-USZUGGBUSA-N (4s)-4-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-[(2s)-2-[[2-[(2s)-2-[[(2s)-1-[[(2s,3r)-1-[[(1s)-1-carboxy-2-methylpropyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1- Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O)C1=CC=C(O)C=C1 POVNCJSPYFCWJR-USZUGGBUSA-N 0.000 description 1
• GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
• HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
• 102000002627 4-1BB Ligand Human genes 0.000 description 1
• 108010082808 4-1BB Ligand Proteins 0.000 description 1
• YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
• 229960005508 8-azaguanine Drugs 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 1
• 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 206010000830 Acute leukaemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 101500002116 Agrotis ipsilon Tachykinin-related peptide 6 Proteins 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 108010064733 Angiotensins Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
• 108010074708 B7-H1 Antigen Proteins 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 206010004593 Bile duct cancer Diseases 0.000 description 1
• 101001011741 Bos taurus Insulin Proteins 0.000 description 1
• 206010006143 Brain stem glioma Diseases 0.000 description 1
• 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
• 102100025221 CD70 antigen Human genes 0.000 description 1
• 102100037904 CD9 antigen Human genes 0.000 description 1
• 108091058556 CTAG1B Proteins 0.000 description 1
• 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 108090000538 Caspase-8 Proteins 0.000 description 1
• 102100028914 Catenin beta-1 Human genes 0.000 description 1
• 102000016362 Catenins Human genes 0.000 description 1
• 108010067316 Catenins Proteins 0.000 description 1
• 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 102100032323 Corticosteroid-binding globulin Human genes 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 241000984642 Cura Species 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
• QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 102100024443 Dihydropyrimidinase-related protein 4 Human genes 0.000 description 1
• 102100028571 Disabled homolog 2-interacting protein Human genes 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 108010035816 E coli chromosomal protein NS2 Proteins 0.000 description 1
• 101150059079 EBNA1 gene Proteins 0.000 description 1
• 101150029707 ERBB2 gene Proteins 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
• 208000036566 Erythroleukaemia Diseases 0.000 description 1
• 108700039887 Essential Genes Proteins 0.000 description 1
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 239000012743 FreeStyle Max reagent Substances 0.000 description 1
• 102100027269 Fructose-bisphosphate aldolase C Human genes 0.000 description 1
• 108010012015 GVYDGREHTV Proteins 0.000 description 1
• 208000000527 Germinoma Diseases 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 108010091373 HA-1 antigen Proteins 0.000 description 1
• 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
• 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
• 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
• 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
• 102000011786 HLA-A Antigens Human genes 0.000 description 1
• 108010075704 HLA-A Antigens Proteins 0.000 description 1
• 108010026122 HLA-A*33 antigen Proteins 0.000 description 1
• 108010035452 HLA-A1 Antigen Proteins 0.000 description 1
• 108010013476 HLA-A24 Antigen Proteins 0.000 description 1
• 108010029526 HLA-A28 antigen Proteins 0.000 description 1
• 108010086377 HLA-A3 Antigen Proteins 0.000 description 1
• 108010018475 HLA-A31 antigen Proteins 0.000 description 1
• 108010058607 HLA-B Antigens Proteins 0.000 description 1
• 108010061486 HLA-B27 Antigen Proteins 0.000 description 1
• 102000012153 HLA-B27 Antigen Human genes 0.000 description 1
• 108010028938 HLA-B45 antigen Proteins 0.000 description 1
• 108010052199 HLA-C Antigens Proteins 0.000 description 1
• 108010037618 HLA-C*08 antigen Proteins 0.000 description 1
• 108010024164 HLA-G Antigens Proteins 0.000 description 1
• 206010066476 Haematological malignancy Diseases 0.000 description 1
• 239000012981 Hank's balanced salt solution Substances 0.000 description 1
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
• 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
• 108010023981 Histone Deacetylase 2 Proteins 0.000 description 1
• 102100039996 Histone deacetylase 1 Human genes 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
• 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
• 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
• 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
• 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
• 101000983528 Homo sapiens Caspase-8 Proteins 0.000 description 1
• 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 description 1
• 101000868967 Homo sapiens Corticosteroid-binding globulin Proteins 0.000 description 1
• 101001053490 Homo sapiens Dihydropyrimidinase-related protein 4 Proteins 0.000 description 1
• 101000915396 Homo sapiens Disabled homolog 2-interacting protein Proteins 0.000 description 1
• 101000836545 Homo sapiens Fructose-bisphosphate aldolase C Proteins 0.000 description 1
• 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
• 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 1
• 101001054807 Homo sapiens Importin subunit alpha-6 Proteins 0.000 description 1
• 101001054793 Homo sapiens Importin subunit alpha-7 Proteins 0.000 description 1
• 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
• 101001034314 Homo sapiens Lactadherin Proteins 0.000 description 1
• 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
• 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 description 1
• 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 description 1
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
• 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
• 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 description 1
• 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 1
• 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 1
• 101001005720 Homo sapiens Melanoma-associated antigen 4 Proteins 0.000 description 1
• 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
• 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 1
• 101001001272 Homo sapiens Prostatic acid phosphatase Proteins 0.000 description 1
• 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 1
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
• 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 1
• 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
• 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
• 101000633608 Homo sapiens Thrombospondin-3 Proteins 0.000 description 1
• 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 1
• 101000808143 Homo sapiens Uroplakin-1a Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
• 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
• 102100027007 Importin subunit alpha-6 Human genes 0.000 description 1
• 102100027002 Importin subunit alpha-7 Human genes 0.000 description 1
• 102000053646 Inducible T-Cell Co-Stimulator Human genes 0.000 description 1
• 108700013161 Inducible T-Cell Co-Stimulator Proteins 0.000 description 1
• 241000713297 Influenza C virus Species 0.000 description 1
• 241001500351 Influenzavirus A Species 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 108020003285 Isocitrate lyase Proteins 0.000 description 1
• 239000007836 KH2PO4 Substances 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 101710191666 Lactadherin Proteins 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• 206010024305 Leukaemia monocytic Diseases 0.000 description 1
• 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
• 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 description 1
• 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 102000018170 Lymphotoxin beta Receptor Human genes 0.000 description 1
• 108010091221 Lymphotoxin beta Receptor Proteins 0.000 description 1
• 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 1
• 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
• 235000019759 Maize starch Nutrition 0.000 description 1
• 101710175243 Major antigen Proteins 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 101710199769 Matrix protein 2 Proteins 0.000 description 1
• 208000007054 Medullary Carcinoma Diseases 0.000 description 1
• 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 101710130208 Melanocyte protein PMEL Proteins 0.000 description 1
• 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
• 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
• 102100025050 Melanoma-associated antigen 1 Human genes 0.000 description 1
• 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 1
• 102100025077 Melanoma-associated antigen 4 Human genes 0.000 description 1
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 206010059282 Metastases to central nervous system Diseases 0.000 description 1
• 108010008707 Mucin-1 Proteins 0.000 description 1
• 102000007298 Mucin-1 Human genes 0.000 description 1
• 102100034256 Mucin-1 Human genes 0.000 description 1
• 241000701029 Murid betaherpesvirus 1 Species 0.000 description 1
• 241000714177 Murine leukemia virus Species 0.000 description 1
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
• LZHSWRWIMQRTOP-UHFFFAOYSA-N N-(furan-2-ylmethyl)-3-[4-[methyl(propyl)amino]-6-(trifluoromethyl)pyrimidin-2-yl]sulfanylpropanamide Chemical compound CCCN(C)C1=NC(=NC(=C1)C(F)(F)F)SCCC(=O)NCC2=CC=CO2 LZHSWRWIMQRTOP-UHFFFAOYSA-N 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 108010088373 Neurofilament Proteins Proteins 0.000 description 1
• 102000008763 Neurofilament Proteins Human genes 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 101800000512 Non-structural protein 1 Proteins 0.000 description 1
• 101800000511 Non-structural protein 2 Proteins 0.000 description 1
• 101800001019 Non-structural protein 4B Proteins 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 1
• 108010058846 Ovalbumin Proteins 0.000 description 1
• 238000009004 PCR Kit Methods 0.000 description 1
• 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
• 206010034016 Paronychia Diseases 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108010089430 Phosphoproteins Proteins 0.000 description 1
• 102000007982 Phosphoproteins Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
• 102100036735 Prostate stem cell antigen Human genes 0.000 description 1
• 102100035703 Prostatic acid phosphatase Human genes 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 102100039641 Protein MFI Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 239000012614 Q-Sepharose Substances 0.000 description 1
• 230000006819 RNA synthesis Effects 0.000 description 1
• 102100038823 RNA-binding protein 45 Human genes 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 208000007660 Residual Neoplasm Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 241000714474 Rous sarcoma virus Species 0.000 description 1
• 201000010208 Seminoma Diseases 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 244000166550 Strophanthus gratus Species 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 239000012505 Superdex™ Substances 0.000 description 1
• 101800001271 Surface protein Proteins 0.000 description 1
• 108700005078 Synthetic Genes Proteins 0.000 description 1
• 230000006044 T cell activation Effects 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 230000005867 T cell response Effects 0.000 description 1
• 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
• 108010017842 Telomerase Proteins 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 102100029524 Thrombospondin-3 Human genes 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108020004566 Transfer RNA Proteins 0.000 description 1
• 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 1
• 102000013532 Uroplakin II Human genes 0.000 description 1
• 108010065940 Uroplakin II Proteins 0.000 description 1
• 108010066197 Uroplakin Ia Proteins 0.000 description 1
• 208000014070 Vestibular schwannoma Diseases 0.000 description 1
• 102000018265 Virus Receptors Human genes 0.000 description 1
• 108010066342 Virus Receptors Proteins 0.000 description 1
• 108700020467 WT1 Proteins 0.000 description 1
• 102000040856 WT1 Human genes 0.000 description 1
• 101150084041 WT1 gene Proteins 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 239000005862 Whey Substances 0.000 description 1
• 108010046377 Whey Proteins Proteins 0.000 description 1
• 102000007544 Whey Proteins Human genes 0.000 description 1
• 108091007916 Zinc finger transcription factors Proteins 0.000 description 1
• 102000038627 Zinc finger transcription factors Human genes 0.000 description 1
• IUHFWCGCSVTMPG-UHFFFAOYSA-N [C].[C] Chemical class [C].[C] IUHFWCGCSVTMPG-UHFFFAOYSA-N 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 208000004064 acoustic neuroma Diseases 0.000 description 1
• 208000017733 acquired polycythemia vera Diseases 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 230000033289 adaptive immune response Effects 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 229940040563 agaric acid Drugs 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 238000004873 anchoring Methods 0.000 description 1
• 238000005349 anion exchange Methods 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 102000025171 antigen binding proteins Human genes 0.000 description 1
• 108091000831 antigen binding proteins Proteins 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 230000037429 base substitution Effects 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 201000007180 bile duct carcinoma Diseases 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 201000000053 blastoma Diseases 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
• 230000006931 brain damage Effects 0.000 description 1
• 231100000874 brain damage Toxicity 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
• 238000010804 cDNA synthesis Methods 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229960004424 carbon dioxide Drugs 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 210000001715 carotid artery Anatomy 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 208000025997 central nervous system neoplasm Diseases 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
• 208000012191 childhood neoplasm Diseases 0.000 description 1
• 108091006116 chimeric peptides Proteins 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000024207 chronic leukemia Diseases 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 210000004081 cilia Anatomy 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 238000010668 complexation reaction Methods 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 108091036078 conserved sequence Proteins 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 208000031513 cyst Diseases 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 210000005220 cytoplasmic tail Anatomy 0.000 description 1
• 230000003436 cytoskeletal effect Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 239000012024 dehydrating agents‎ Substances 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
• UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 201000008184 embryoma Diseases 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 239000012645 endogenous antigen Substances 0.000 description 1
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 238000007824 enzymatic assay Methods 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 238000011067 equilibration Methods 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 238000013209 evaluation strategy Methods 0.000 description 1
• 238000007387 excisional biopsy Methods 0.000 description 1
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 238000001215 fluorescent labelling Methods 0.000 description 1
• 102000034287 fluorescent proteins Human genes 0.000 description 1
• 108091006047 fluorescent proteins Proteins 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 201000003115 germ cell cancer Diseases 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 230000002710 gonadal effect Effects 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 210000005003 heart tissue Anatomy 0.000 description 1
• 208000025750 heavy chain disease Diseases 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 201000002222 hemangioblastoma Diseases 0.000 description 1
• 208000013210 hematogenous Diseases 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 230000009033 hematopoietic malignancy Effects 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 230000028996 humoral immune response Effects 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 125000001165 hydrophobic group Chemical group 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 210000001822 immobilized cell Anatomy 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 230000005965 immune activity Effects 0.000 description 1
• 229940126546 immune checkpoint molecule Drugs 0.000 description 1
• 230000007124 immune defense Effects 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 229940127121 immunoconjugate Drugs 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000010921 in-depth analysis Methods 0.000 description 1
• 238000007386 incisional biopsy Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 108010046023 influenza B virus nucleoprotein Proteins 0.000 description 1
• 108010061181 influenza matrix peptide (58-66) Proteins 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000010212 intracellular staining Methods 0.000 description 1
• 238000000185 intracerebroventricular administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 238000012977 invasive surgical procedure Methods 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 239000004922 lacquer Substances 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 108010003486 leucyl-leucyl-phenylalanyl-glycyl-tyrosyl-prolyl-valyl-tyrosyl-valine Proteins 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 239000012160 loading buffer Substances 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 201000005249 lung adenocarcinoma Diseases 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 230000008099 melanin synthesis Effects 0.000 description 1
• 210000002752 melanocyte Anatomy 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 239000010445 mica Substances 0.000 description 1
• 229910052618 mica group Inorganic materials 0.000 description 1
• 238000012737 microarray-based gene expression Methods 0.000 description 1
• 230000002906 microbiologic effect Effects 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 235000021243 milk fat Nutrition 0.000 description 1
• 201000004058 mixed glioma Diseases 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 108091005601 modified peptides Proteins 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 201000006894 monocytic leukemia Diseases 0.000 description 1
• 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
• 235000019796 monopotassium phosphate Nutrition 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• 208000001611 myxosarcoma Diseases 0.000 description 1
• VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 208000025189 neoplasm of testis Diseases 0.000 description 1
• 208000007538 neurilemmoma Diseases 0.000 description 1
• 210000005044 neurofilament Anatomy 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 229920000620 organic polymer Polymers 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 239000003791 organic solvent mixture Substances 0.000 description 1
• 210000000963 osteoblast Anatomy 0.000 description 1
• LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
• 229960003343 ouabain Drugs 0.000 description 1
• 229940092253 ovalbumin Drugs 0.000 description 1
• 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
• 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 210000004923 pancreatic tissue Anatomy 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
• 201000010198 papillary carcinoma Diseases 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 208000028591 pheochromocytoma Diseases 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 208000024724 pineal body neoplasm Diseases 0.000 description 1
• 201000004123 pineal gland cancer Diseases 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 208000037244 polycythemia vera Diseases 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 238000012910 preclinical development Methods 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 239000000955 prescription drug Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 238000012514 protein characterization Methods 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000004063 proteosomal degradation Effects 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 210000004879 pulmonary tissue Anatomy 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 210000003289 regulatory T cell Anatomy 0.000 description 1
• 210000005084 renal tissue Anatomy 0.000 description 1
• BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
• 230000008521 reorganization Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 229940100486 rice starch Drugs 0.000 description 1
• 206010039667 schwannoma Diseases 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 238000007493 shaping process Methods 0.000 description 1
• 239000013605 shuttle vector Substances 0.000 description 1
• 238000001542 size-exclusion chromatography Methods 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000015424 sodium Nutrition 0.000 description 1
• 239000007974 sodium acetate buffer Substances 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 239000012439 solid excipient Substances 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 238000005728 strengthening Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 238000004114 suspension culture Methods 0.000 description 1
• 201000010965 sweat gland carcinoma Diseases 0.000 description 1
• 206010042863 synovial sarcoma Diseases 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
• 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 230000005026 transcription initiation Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 230000004222 uncontrolled growth Effects 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 230000002861 ventricular Effects 0.000 description 1
• 230000036642 wellbeing Effects 0.000 description 1
• 229940100445 wheat starch Drugs 0.000 description 1
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1